

Eugene Braunwald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4058237/publications.pdf>

Version: 2024-02-01

401
papers

74,809
citations

1799

103
h-index

517

267
g-index

406
all docs

406
docs citations

406
times ranked

39554
citing authors

#	ARTICLE	IF	CITATIONS
1	How to live to 100 before developing clinical coronary artery disease: a suggestion. <i>European Heart Journal</i> , 2022, 43, 249-250.	2.2	20
2	Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 895-902.	1.8	18
3	SGLT2 inhibitors: the statins of the 21st century. <i>European Heart Journal</i> , 2022, 43, 1029-1030.	2.2	45
4	Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2022, 7, 17.	6.1	77
5	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. <i>Circulation</i> , 2022, 145, 87-89.	1.6	28
6	Association of Apolipoprotein Bâ€“Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. <i>JAMA Cardiology</i> , 2022, 7, 250.	6.1	108
7	Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups. <i>American Heart Journal</i> , 2022, 247, 24-32.	2.7	6
8	Heart failure: a 70 year Odyssey. <i>European Heart Journal</i> , 2022, 43, 1697-1699.	2.2	3
9	Cardiovascular Events and Longâ€“Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVEâ€“IT. <i>Journal of the American Heart Association</i> , 2022, 11, e022733.	3.7	4
10	Changing the Trajectory of Heart Failure and Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, , CJN.00470122.	4.5	2
11	Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 695-706.	3.0	5
12	Cardiac cell therapy: a call for action. <i>European Heart Journal</i> , 2022, 43, 2352-2353.	2.2	8
13	Could Nephilysin Be Already Inhibited by BNP in the LIFE Trial?â€“Reply. <i>JAMA Cardiology</i> , 2022, , .	6.1	0
14	Gliflozins in the Management of Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2022, 386, 2024-2034.	27.0	113
15	Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58â€“634 patients across four randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f40-f49.	3.0	13
16	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , 2021, 143, 470-478.	1.6	32
17	Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. <i>Thrombosis and Haemostasis</i> , 2021, 121, 140-149.	3.4	22
18	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. <i>Circulation</i> , 2021, 143, 685-695.	1.6	22

#	ARTICLE	IF	CITATIONS
19	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003006.	3.6	6
20	Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e007034.	3.9	27
21	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2021, 143, 673-684.	1.6	10
22	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2021, 10, e017008.	3.7	17
23	Cardiology in 2021. <i>European Heart Journal</i> , 2021, 42, 959-959.	2.2	5
24	Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2021, 42, 1698-1706.	2.2	27
25	The path to universality. <i>European Journal of Heart Failure</i> , 2021, 23, 381-383.	7.1	2
26	The Birth of Cardiology: The Golden Decade. <i>European Heart Journal</i> , 2021, 42, 1650-1651.	2.2	2
27	Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1197-1207.	2.8	29
28	Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2021, 23, 1040-1048.	7.1	70
29	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. <i>Journal of Clinical Neuroscience</i> , 2021, 86, 294-300.	1.5	5
30	Transseptal left heart catheterization: birth, death, and resurrection. <i>European Heart Journal</i> , 2021, 42, 2327-2328.	2.2	0
31	The war on heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 915-916.	7.1	2
32	Reflections on Hypertrophic Cardiomyopathy. <i>European Heart Journal</i> , 2021, 42, 2969-2970.	2.2	3
33	Thrombolysis In Myocardial Infarction (TIMI) Study Group. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2822-2845.	2.8	23
34	Cholesterol: the race to the bottom. <i>European Heart Journal</i> , 2021, 42, 4612-4613.	2.2	10
35	A new initiative of the European Heart Journal: the Desmond Julian Award. <i>European Heart Journal</i> , 2021, 42, 3894-3895.	2.2	1
36	Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1818-1824.	30.7	51

#	ARTICLE	IF	CITATIONS
37	Long-term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. Journal of the American Heart Association, 2021, 10, e020446.	3.7	7
38	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care, 2021, 44, 2573-2581.	8.6	13
39	Heart failure with preserved ejection fraction: a stepchild no more!. European Heart Journal, 2021, 42, 3900-3901.	2.2	13
40	A tribute to Attilio Maseri. European Heart Journal, 2021, 42, 4410-4412.	2.2	3
41	Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. Journal of the American College of Cardiology, 2021, 78, 1499-1507.	2.8	22
42	Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. Journal of Cardiac Failure, 2020, 26, 371-380.	1.7	25
43	Atrial Failure as a Clinical Entity. Journal of the American College of Cardiology, 2020, 75, 222-232.	2.8	174
44	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. European Heart Journal, 2020, 41, 1625-1632.	2.2	27
45	Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial). American Journal of Cardiology, 2020, 125, 661-669.	1.6	7
46	Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure. JAMA Cardiology, 2020, 5, 202.	6.1	57
47	Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. Journal of the American College of Cardiology, 2020, 76, 1034-1048.	2.8	32
48	Angiotensin-Neprilysin Inhibition in Black Americans. JACC: Heart Failure, 2020, 8, 859-866.	4.1	11
49	Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. JACC: Heart Failure, 2020, 8, 834-843.	4.1	19
50	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. JAMA Cardiology, 2020, 5, 1255.	6.1	27
51	Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2020, 5, 1236.	6.1	46
52	Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006511.	2.2	6
53	Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet, The, 2020, 396, 1637-1643.	13.7	167
54	Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo. JACC: CardioOncology, 2020, 2, 385-396.	4.0	7

#	ARTICLE	IF	CITATIONS
55	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. <i>European Heart Journal</i> , 2020, 41, 3255-3268.	2.2	49
56	Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 789-799.	4.1	39
57	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	2.2	65
58	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1095-1106.	2.8	25
59	Managing Stable Ischemic Heart Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1468-1470.	27.0	36
60	Association of Hypertrophic Obstructive Cardiomyopathy With Outcomes Following Transcatheter Aortic Valve Replacement. <i>JAMA Network Open</i> , 2020, 3, e1921669.	5.9	14
61	Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2020, 75, 422-434.	2.8	302
62	Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2020, 75, 435-447.	2.8	65
63	Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2020, 304, 185-191.	1.7	25
64	Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 176-185.	1.0	18
65	Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs. <i>Cardiac Failure Review</i> , 2019, 5, 27-30.	3.0	7
66	Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. <i>Hypertension</i> , 2019, 74, 597-605.	2.7	16
67	Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older. <i>JAMA Cardiology</i> , 2019, 4, 846.	6.1	81
68	The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. <i>Cell Metabolism</i> , 2019, 30, 847-849.	16.2	39
69	Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2019, 140, 1792-1801.	1.6	22
70	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 1569-1577.	1.6	94
71	In Memoriam—John Ross Jr, MD. <i>JAMA Cardiology</i> , 2019, 4, 967.	6.1	1
72	Diabetes, heart failure, and renal dysfunction: The vicious circles. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 298-302.	3.1	151

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 200-206.	3.0	25
74	The Evidence Supporting Cardiovascular Guidelines. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1053.	7.4	11
75	Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. <i>Circulation</i> , 2019, 139, 2285-2288.	1.6	129
76	Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. <i>European Journal of Heart Failure</i> , 2019, 21, 1571-1579.	7.1	44
77	Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3013-3022.	2.8	54
78	Baseline Characteristics of the VANISH Cohort. <i>Circulation: Heart Failure</i> , 2019, 12, e006231.	3.9	10
79	Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2019, 40, 1518-1527.	2.2	67
80	Angiotensin Neprilysin Inhibition in Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2019, 380, 539-548.	27.0	848
81	Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Circulation</i> , 2019, 139, 760-771.	1.6	99
82	Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial. <i>Europace</i> , 2019, 21, 306-312.	1.7	6
83	Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2019, 40, 1541-1550.	2.2	88
84	Medication Discontinuation in the IMPROVE-IT Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005041.	2.2	23
85	Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). <i>American Journal of Cardiology</i> , 2019, 123, 145-152.	1.6	25
86	Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 186-193.	1.0	12
87	Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. <i>Journal of Cardiac Failure</i> , 2018, 24, 255-265.	1.7	32
88	André Cournand, Bellevue's Cardiopulmonary Laboratory, and Research on Heart Failure. <i>Annals of the American Thoracic Society</i> , 2018, 15, S12-S14.	3.2	0
89	Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2018, 3, 473.	6.1	33
90	Aortic Stenosis. <i>Circulation</i> , 2018, 137, 2099-2100.	1.6	40

#	ARTICLE	IF	CITATIONS
91	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 489-496.	2.8	56
92	Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2018, 257, 102-107.	1.7	18
93	Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus. <i>Circulation</i> , 2018, 137, 1571-1582.	1.6	304
94	Rationale and design of the comparison of sacubitril/valsartan versus Enalapril on Effect on natriuretic peptide (NT-pro-BNP) in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. <i>American Heart Journal</i> , 2018, 198, 145-151.	2.7	60
95	Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1001-1008.	3.4	18
96	Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 830-838.	1.8	20
97	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <i>Circulation</i> , 2018, 137, 684-692.	1.6	22
98	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1764.	7.4	187
99	Treatment of Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1751.	7.4	30
100	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. <i>Journal of the American Heart Association</i> , 2018, 7, e009260.	3.7	8
101	Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial). <i>American Journal of Cardiology</i> , 2018, 122, 1896-1901.	1.6	17
102	Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 934-943.	11.4	96
103	Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1466-1475.	2.8	10
104	Modes and timing of death in 66,252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , 2018, 39, 3810-3820.	2.2	28
105	Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2018, 72, 129-136.	2.8	12
106	Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2018, 138, 1963-1973.	1.6	32
107	Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1845-1855.	2.8	190
108	Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. <i>American Journal of Cardiology</i> , 2018, 122, 1451-1458.	1.6	2

#	ARTICLE	IF	CITATIONS
109	Cell-Based Therapy in Cardiac Regeneration. <i>Circulation Research</i> , 2018, 123, 132-137.	4.5	67
110	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 856-864.	2.9	25
111	Gastrointestinal Bleeding With Edoxaban Versus Warfarin. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e003998.	2.2	33
112	D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy). <i>American Journal of Cardiology</i> , 2018, 122, 1459-1464.	1.6	21
113	Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved) Tj ETQq1 1 0.784314 rgBTd/Overlo	3.1	47
114	Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2 [°] P-TIMI 50 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 164-172.	1.0	8
115	A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. <i>European Heart Journal</i> , 2017, 38, ehw565.	2.2	37
116	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	4.8	139
117	Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib Thrombolysis in Myocardial Infarction 52 (SOLIDATE-TIMI 52) Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	8
118	Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 911-921.	2.8	157
119	The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial. <i>American Heart Journal</i> , 2017, 187, 145-155.	2.7	41
120	Soluble ST2 in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	64
121	Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1958.	7.4	329
122	Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	8
123	INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved) Tj ETQq1 1 0.784314 rgBT /Overlo	3.9	47
124	Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, e003878.	3.9	45
125	Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE [®] AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1372-1382.	2.8	111
126	Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol. <i>JAMA Cardiology</i> , 2017, 2, 547.	6.1	144

#	ARTICLE	IF	CITATIONS
127	Microangiopathy, Arterial Stiffness, and Risk Stratification in Patients With Type 2 Diabetes—Reply. JAMA Cardiology, 2017, 2, 821.	6.1	0
128	Potent P2Y ₁₂ Inhibitors in Men Versus Women. Journal of the American College of Cardiology, 2017, 69, 1549-1559.	2.8	51
129	High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2-P - TIMI 50 Trial. Clinical Chemistry, 2017, 63, 307-315.	3.2	19
130	Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International) Trial. JAMA Cardiology, 2017, 2, 821.	6.1	0
131	An Important Step for Thrombocardiology. New England Journal of Medicine, 2017, 377, 1387-1388.	27.0	18
132	Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. New England Journal of Medicine, 2017, 377, 1217-1227.	27.0	780
133	Cardiomyopathies. Circulation Research, 2017, 121, 711-721.	4.5	106
134	Hypertrophic Cardiomyopathy. Circulation Research, 2017, 121, 749-770.	4.5	790
135	Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. Journal of the American College of Cardiology, 2017, 70, 1368-1375.	2.8	74
136	Achieving Extended Longevity and Quality of Life for Senior Patients With Hypertrophic Cardiomyopathy: What Is Possible. American Journal of Medicine, 2017, 130, 1236-1237.	1.5	2
137	Efficacy and Safety of Spironolactone in Acute Heart Failure. JAMA Cardiology, 2017, 2, 950.	6.1	199
138	Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial. Journal of the American Heart Association, 2017, 6, .	3.7	30
139	Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care, 2017, 40, 69-76.	8.6	205
140	Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored Until Now. American Journal of Medicine, 2017, 130, 119-123.	1.5	17
141	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. European Heart Journal, 2016, 37, ehv443.	2.2	293
142	Prevalence, Profile, and Prognosis of Severe Obesity in Contemporary Hospitalized Heart Failure Trial Populations. JACC: Heart Failure, 2016, 4, 923-931.	4.1	40
143	Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial. Journal of the American Heart Association, 2016, 5, .	3.7	53
144	Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT." Circulation, 2016, 133, e463.	1.6	0

#	ARTICLE	IF	CITATIONS
145	Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. Diabetes Care, 2016, 39, 1329-1337.	8.6	12
146	Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AFâ€“TIMI 48 Trial. Journal of the American Heart Association, 2016, 5, .	3.7	215
147	Intravenous Beta-Blockade for Limitingâˆ“Myocardial Infarct Size. Journal of the American College of Cardiology, 2016, 67, 2105-2107.	2.8	3
148	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2016, 67, 2719-2728.	2.8	303
149	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUSâ€“TIMI 54. Journal of the American College of Cardiology, 2016, 67, 2732-2740.	2.8	179
150	Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	3.9	38
151	The Prognostic Significance of Cardiac Structure andâˆ“Function in Atrial Fibrillation: The ENGAGE AFâ€“TIMI 48 Echocardiographic Substudy. Journal of the American Society of Echocardiography, 2016, 29, 537-544.	2.8	29
152	Edoxaban Versus Warfarin in Atrialâˆ“Fibrillation Patients at Risk of Falling. Journal of the American College of Cardiology, 2016, 68, 1169-1178.	2.8	133
153	Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. JAMA - Journal of the American Medical Association, 2016, 316, 1289.	7.4	974
154	Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation. JAMA Cardiology, 2016, 1, 999.	6.1	64
155	Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2016, 316, 500.	7.4	457
156	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. Stroke, 2016, 47, 2075-2082.	2.0	83
157	Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from <scp>ENGAGE AFâ€“TIMI</scp> 48. European Journal of Heart Failure, 2016, 18, 1153-1161.	7.1	73
158	Rationale and Design of the ATHENA-HF Trial. JACC: Heart Failure, 2016, 4, 726-735.	4.1	30
159	Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2âˆ“P)â€“TIMI 50. Journal of the American Heart Association, 2016, 5, .	3.7	13
160	The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. European Heart Journal, 2016, 37, 3576-3584.	2.2	71
161	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction. Circulation, 2016, 134, 861-871.	1.6	40
162	Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AFâ€“TIMI48 Trial. Journal of the American Heart Association, 2016, 5, .	3.7	93

#	ARTICLE	IF	CITATIONS
163	Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. <i>Circulation</i> , 2016, 134, 304-313.	1.6	143
164	Updates on Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016, 1, 718.	6.1	127
165	Circulation : The Beat Goes On. <i>Circulation</i> , 2016, 134, 6-8.	1.6	6
166	Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2016, 134, 24-36.	1.6	234
167	Treatment of Left Main Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2016, 375, 2284-2285.	27.0	16
168	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events. <i>JAMA Cardiology</i> , 2016, 1, 425.	6.1	88
169	Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. <i>American Journal of Medicine</i> , 2016, 129, 850-857.e2.	1.5	58
170	Reduction of LDL-cholesterol: important at all ages. <i>European Heart Journal</i> , 2016, 37, 1982-1984.	2.2	5
171	Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50). <i>American Journal of Cardiology</i> , 2016, 117, 1055-1058.	1.6	5
172	Treatment of Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2016, 1, 7.	6.1	35
173	Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure: Table A1. <i>European Heart Journal</i> , 2016, 37, 745-746.	2.2	4
174	Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1145-1154.	2.8	108
175	Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation—Thrombolysis in Myocardial Infarction 48 (ENGAGE AF—TIMI 48) trial. <i>American Heart Journal</i> , 2016, 172, 144-151.	2.7	13
176	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y ₁₂ inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2016, 37, 1133-1142.	2.2	138
177	Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. <i>American Journal of Medicine</i> , 2016, 129, 340.e1-340.e8.	1.5	34
178	Another step toward personalized care of patients with heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 988-990.	7.1	11
179	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015, 372, 2387-2397.	27.0	3,337
180	Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. <i>European Heart Journal</i> , 2015, 36, 1470-1477.	2.2	47

#	ARTICLE	IF	CITATIONS
181	Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet, The</i> , 2015, 385, 2288-2295.	13.7	335
182	Cardiovascular pharmacology: a look back and a glimpse into the future. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 7-9.	3.0	5
183	Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 97-107.	4.1	95
184	Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 431-440.	1.0	17
185	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet, The</i> , 2015, 385, 2280-2287.	13.7	153
186	The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1029-1041.	2.8	133
187	Progress in the Noninvasive Detection of High-Risk Coronary Plaques. <i>Journal of the American College of Cardiology</i> , 2015, 66, 347-349.	2.8	8
188	Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. <i>Europace</i> , 2015, 17, 32-37.	1.7	46
189	Galectin-3 in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 245-252.	4.1	49
190	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. <i>New England Journal of Medicine</i> , 2015, 372, 1791-1800.	27.0	1,585
191	Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2015, 38, 1145-1153.	8.6	73
192	Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". <i>Circulation</i> , 2015, 132, e121-2.	1.6	61
193	Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT. <i>Circulation</i> , 2015, 132, 1224-1233.	1.6	267
194	Causes of late mortality with dual antiplatelet therapy after coronary stents. <i>European Heart Journal</i> , 2015, 37, ehv614.	2.2	38
195	Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack. <i>Circulation</i> , 2015, 132, 1871-1879.	1.6	39
196	The war against heart failure: the Lancet lecture. <i>Lancet, The</i> , 2015, 385, 812-824.	13.7	646
197	Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. <i>European Heart Journal</i> , 2014, 35, 1457-1465.	2.2	174
198	Coronary Stent Thrombosis With Vorapaxar Versus Placebo. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2309-2317.	2.8	41

#	ARTICLE	IF	CITATIONS
199	Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2014, 312, 1006.	7.4	375
200	Recognizing Worsening Chronic Heart Failure as an Entity and an End Point in Clinical Trials. JAMA - Journal of the American Medical Association, 2014, 312, 789.	7.4	58
201	Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin. Stroke, 2014, 45, 2372-2378.	2.0	46
202	GLP-1 Agonist Therapy for Advanced Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2014, 7, 673-679.	3.9	41
203	Responsiveness to loop diuretics in heart failure. European Heart Journal, 2014, 35, 1235-1237.	2.2	14
204	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin—Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal, 2014, 167, 437-444.e5.	2.7	89
205	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet, The, 2014, 383, 955-962.	13.7	3,942
206	The Year in Acute Coronary Syndrome. Journal of the American College of Cardiology, 2014, 63, 201-214.	2.8	14
207	Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. New England Journal of Medicine, 2014, 371, 2155-2166.	27.0	1,645
208	Prasugrel Versus Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction According to Timing of Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 604-612.	2.9	45
209	Fondation Leducq. Circulation Research, 2014, 115, 419-422.	4.5	2
210	Transition of Patients From Blinded Study—Drug to Open-Label Anticoagulation. Journal of the American College of Cardiology, 2014, 64, 576-584.	2.8	39
211	Resting Ventricular—Vascular Function and Exercise Capacity in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 580-589.	3.9	40
212	Angiographic Outcomes With Early Eptifibatide Therapy in Non—ST-Segment Elevation Acute Coronary Syndrome (from the EARLY ACS Trial). American Journal of Cardiology, 2014, 113, 1297-1305.	1.6	10
213	Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. American Heart Journal, 2014, 168, 205-212.e1.	2.7	93
214	The ten advances that have defined modern cardiology. Trends in Cardiovascular Medicine, 2014, 24, 179-183.	4.9	13
215	Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine, 2013, 369, 1317-1326.	27.0	3,017
216	Unstable Angina. Circulation, 2013, 127, 2452-2457.	1.6	186

#	ARTICLE	IF	CITATIONS
217	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2013, 369, 2093-2104.	27.0	4,215
218	Cardiac Troponin After Percutaneous Coronary Intervention and 1-Year Mortality in Non-ST-Segment Elevation Acute Coronary Syndrome Using Systematic Evaluation of Biomarker Trends. Journal of the American College of Cardiology, 2013, 62, 242-251.	2.8	39
219	Research Advances in Heart Failure. Circulation Research, 2013, 113, 633-645.	4.5	59
220	Heart Failure. JACC: Heart Failure, 2013, 1, 1-20.	4.1	612
221	CardioPulse Articles. European Heart Journal, 2013, 34, 943-948.	2.2	1
222	Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. JAMA - Journal of the American Medical Association, 2013, 310, 2533.	7.4	410
223	Burton E. Sobel: 1937-2013. Circulation, 2013, 128, 188-189.	1.6	0
224	Cardiovascular science: opportunities for translating research into improved care. Journal of Clinical Investigation, 2013, 123, 6-10.	8.2	26
225	The rise of cardiovascular medicine. European Heart Journal, 2012, 33, 838-845.	2.2	59
226	Hypertrophic cardiomyopathy: The first century 1869-1969. Global Cardiology Science & Practice, 2012, 2012, 5.	0.4	6
227	The Thrombolysis in Myocardial Infarction (TIMI) Study Group experience. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, 762-770.	0.8	14
228	The treatment of acute myocardial infarction: the Past, the Present, and the Future. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 9-12.	1.0	55
229	Unstable Angina and Non-ST Elevation Myocardial Infarction. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 924-932.	5.6	66
230	Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine, 2012, 366, 9-19.	27.0	1,681
231	Vorapaxar in the Secondary Prevention of Atherothrombotic Events. New England Journal of Medicine, 2012, 366, 1404-1413.	27.0	841
232	The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2011, 58, 2342-2354.	2.8	7
233	Study design and rationale for the Stabilization of pLaques using Darapladib Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. American Heart Journal, 2011, 162, 613-619.e1.	2.7	77
234	Clinical Efforts to Reduce Myocardial Infarct Size The Next Step. Journal of Cardiovascular Pharmacology and Therapeutics, 2011, 16, 349-353.	2.0	19

#	ARTICLE	IF	CITATIONS
235	HMG CoA Reduction in Patients with Average Cholesterol Concentrations. <i>Clinical Chemistry</i> , 2011, 57, 1072-1073.	3.2	2
236	Response to Letter Regarding Article, "Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38". <i>Circulation</i> , 2010, 122, .	1.6	1
237	Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective anticoagulation with factor xA next Generation in Atrial Fibrillation"Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF"TIMI 48). <i>American Heart Journal</i> , 2010, 160, 635-641.e2.	2.7	439
238	Adventures in Cardiovascular Research. <i>Circulation</i> , 2009, 120, 170-180.	1.6	22
239	Hypertrophic Cardiomyopathy: The Early Years. <i>Journal of Cardiovascular Translational Research</i> , 2009, 2, 341-348.	2.4	15
240	Preface. <i>Heart Failure Clinics</i> , 2009, 5, xiii-xiv.	2.1	11
241	Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. <i>Lancet</i> , The, 2009, 374, 989-997.	13.7	650
242	JACC: Cardiovascular Interventions: The End of the Beginning. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 1-2.	2.9	24
243	Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2008, 31, 128-135.	1.8	2
244	Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches. <i>Clinical Cardiology</i> , 2008, 31, 121-127.	1.8	7
245	Assessing the Current Role of Platelet Function Testing. <i>Clinical Cardiology</i> , 2008, 31, 110-116.	1.8	26
246	Antiplatelet Strategies: Evaluating Their Current Role in the Setting of Acute Coronary Syndromes. <i>Clinical Cardiology</i> , 2008, 31, 12-19.	1.8	9
247	The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2008, 31, 117-120.	1.8	33
248	Antiplatelet Therapy and Platelet Function Testing. <i>Clinical Cardiology</i> , 2008, 31, 11-11.	1.8	2
249	Antiplatelet Therapy and Platelet Function Testing. <i>Clinical Cardiology</i> , 2008, 31, 136-136.	1.8	7
250	Biomarkers in Heart Failure. <i>New England Journal of Medicine</i> , 2008, 358, 2148-2159.	27.0	1,111
251	The Year in Non"ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1095-1103.	2.8	9
252	Summary of Issues Emanating from the Workshop on Congestive Heart Failure. <i>Artificial Organs</i> , 2008, 6, 342-344.	1.9	0

#	ARTICLE	IF	CITATIONS
253	The Management of Heart Failure. Circulation: Heart Failure, 2008, 1, 58-62.	3.9	28
254	The American Society for Clinical Investigation, 1952–1975: a personal perspective. Journal of Clinical Investigation, 2008, 118, 1228-1230.	8.2	2
255	Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non–ST-Elevation Acute Coronary Syndromes<SUBTITLE>The MERLIN-TIMI 36 Randomized Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2007, 297, 1775.	7.4	448
256	Reducing Myocardial Injury by Minimizing Imbalance between Oxygen Supply and Demand. Anesthesiology, 2007, 107, 161-163.	2.5	1
257	The Year in Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2007, 50, 1386-1395.	2.8	3
258	Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2007, 357, 2001-2015.	27.0	5,933
259	Epilogue: What Do Clinicians Expect From Imagers?. Journal of the American College of Cardiology, 2006, 47, C101-C103.	2.8	74
260	The Year in Non–ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2006, 48, 386-395.	2.8	5
261	Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy. Journal of the American College of Cardiology, 2005, 46, 1411-1416.	2.8	306
262	The Year in Non-ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2005, 46, 906-919.	2.8	40
263	Cardiology: how did we get here, where are we today and where are we going?. Canadian Journal of Cardiology, 2005, 21, 1015-7.	1.7	5
264	Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. New England Journal of Medicine, 2004, 350, 1495-1504.	27.0	4,527
265	Age and Routine Invasive Management of Acute Coronary Syndromes. Annals of Internal Medicine, 2004, 141, 967.	3.9	0
266	Cardiology: the past, the present, and the future. Journal of the American College of Cardiology, 2003, 42, 2031-2041.	2.8	49
267	Application of Current Guidelines to the Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction. Circulation, 2003, 108, 28III-37.	1.6	52
268	Contemporary Evaluation and Management of Hypertrophic Cardiomyopathy. Circulation, 2002, 106, 1312-1316.	1.6	160
269	Hypertrophic Cardiomyopathy – The Benefits of a Multidisciplinary Approach. New England Journal of Medicine, 2002, 347, 1306-1307.	27.0	12
270	Prognosis in the Thrombolysis in Myocardial Ischemia III Registry according to the Braunwald unstable angina pectoris classification. American Journal of Cardiology, 2002, 90, 821-826.	1.6	19

#	ARTICLE	IF	CITATIONS
271	Changing the practice of cardiovascular medicine. <i>Atherosclerosis Supplements</i> , 2001, 2, 27-30.	1.2	4
272	Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 53, 6-11.	1.7	8
273	Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction. <i>Circulation</i> , 2001, 103, 2550-2554.	1.6	440
274	Results of the Treat Angina With Aggrastat and Determine the Cost of Therapy With an Invasive or Conservative Strategy (TACTICS-TIMI 18) Trial: A Comparison of Invasive Versus Conservative Strategy in Patients With Unstable Angina and Non- σ ST-Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2000, 102, 2672-2672.	1.6	7
275	TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation. <i>Circulation</i> , 2000, 102, 2031-2037.	1.6	1,302
276	A Classification of Unstable Angina Revisited. <i>Circulation</i> , 2000, 102, 118-122.	1.6	348
277	Reexamination of the Thrombin Hypothesis: What We Have Learned from TIMI 9B and GUSTO IIb. <i>Journal of Thrombosis and Thrombolysis</i> , 1997, 4, 321-323.	2.1	0
278	Induced Septal Infarction. <i>Circulation</i> , 1997, 95, 1981-1982.	1.6	34
279	The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. <i>New England Journal of Medicine</i> , 1996, 335, 1001-1009.	27.0	7,059
280	Time to reperfusion: The critical modulator in thrombolysis and primary angioplasty. <i>Journal of Thrombosis and Thrombolysis</i> , 1996, 3, 117-125.	2.1	32
281	Morning Resistance to Thrombolytic Therapy. <i>Circulation</i> , 1995, 91, 1604-1606.	1.6	41
282	Tissue plasminogen activator and acute pulmonary embolism. <i>Journal of Cellular Biochemistry</i> , 1988, 38, 303-312.	2.6	5
283	Fraud and other matters?. <i>Nature</i> , 1987, 328, 196-196.	27.8	0
284	Effects of Chronic Heart Failure on the Inotropic Response of the Right Ventricle of the Conscious Dog to a Cardiac Glycoside and to Tachycardia. <i>Circulation</i> , 1974, 50, 728-734.	1.6	26
285	Assessment of Left Ventricular Performance in Man. <i>Circulation</i> , 1973, 47, 924-935.	1.6	42
286	Protection of the Ischemic Myocardium. <i>Hospital Practice</i> (1995), 1973, 8, 61-74.	1.0	13
287	Assessment of Cardiac Contractility. <i>Circulation</i> , 1971, 44, 47-58.	1.6	228
288	Effects of hyperlipoproteinemias and their treatment on the peripheral circulation. <i>Journal of Clinical Investigation</i> , 1970, 49, 1007-1015.	8.2	132

#	ARTICLE	IF	CITATIONS
289	Circulatory Effects of Electrical Stimulation of the Carotid Sinus Nerves in Man. Circulation, 1969, 40, 269-276.	1.6	79
290	Partition of Blood Flow to the Cutaneous and Muscular Beds of the Forearm at Rest and during Leg Exercise in Normal Subjects and in Patients with Heart Failure. Circulation Research, 1969, 24, 799-806.	4.5	152
291	Mechanochemistry of Cardiac Muscle. Circulation Research, 1969, 24, 313-320.	4.5	18
292	EFFECTS OF HEART FAILURE, VENTRICULAR HYPERTROPHY, AND ALTERATIONS IN THE THYROID STATE ON THE CONTRACTILITY OF ISOLATED CARDIAC MUSCLE. Annals of the New York Academy of Sciences, 1969, 156, 379-386.	3.8	7
293	Operative Treatment in Idiopathic Hypertrophic Subaortic Stenosis. Circulation, 1968, 37, 589-596.	1.6	127
294	Augmented Sympathetic Neurotransmitter Activity in the Peripheral Vascular Bed of Patients with Congestive Heart Failure and Cardiac Norepinephrine Depletion. Circulation, 1968, 38, 629-634.	1.6	87
295	Contractile State of the Left Ventricle in Man. Circulation Research, 1968, 22, 451-463.	4.5	281
296	Integrity of Energy Stores in Cat Papillary Muscle. Circulation Research, 1968, 22, 213-219.	4.5	24
297	Impaired Rate of Left Ventricular Filling in Idiopathic Hypertrophic Subaortic Stenosis and Valvular Aortic Stenosis. Circulation, 1968, 37, 8-14.	1.6	172
298	Idiopathic Hypertrophic Subaortic Stenosis. Circulation, 1968, 37, 759-788.	1.6	557
299	Effects of Acute Valvular Regurgitation on the Oxygen Consumption of the Canine Heart. Circulation Research, 1968, 23, 33-43.	4.5	45
300	Severe Mitral Regurgitation Following Acute Myocardial Infarction and Ruptured Papillary Muscle. Circulation, 1968, 37, .	1.6	28
301	Chapter 4: Deaths Related to Cardiac Catheterization. Circulation, 1968, 37, .	1.6	13
302	Chapter 17: Transseptal Left Heart Catheterization. Circulation, 1968, 37, .	1.6	7
303	Chapter 18: Percutaneous Left Ventricular Puncture. Circulation, 1968, 37, .	1.6	5
304	Aortic Stenosis. Circulation, 1968, 38, 61-7.	1.6	910
305	Chapter 13: Severe Hypotension. Circulation, 1968, 37, .	1.6	0
306	Characterization of the Circulatory Response to Maximal Upright Exercise in Normal Subjects and Patients with Heart Disease. Circulation, 1967, 35, 1049-1062.	1.6	150

#	ARTICLE	IF	CITATIONS
307	The Effects of Mitral Regurgitation on the Pattern of Instantaneous Aortic Blood Flow Clinical and Experimental Observations. Circulation, 1967, 36, 45-53.	1.6	24
308	Effects of Frequency of Contraction and Ionic Environment on the Responses of Heart Muscle to Acetylcholine. Circulation Research, 1967, 21, 573-582.	4.5	30
309	Significance of an Atrial Gallop Sound in Mitral Regurgitation. Circulation, 1967, 35, 112-118.	1.6	48
310	Interactions between Changes in the Intensity and Duration of the Active State in the Characterization of Inotropic Stimuli on Heart Muscle. Circulation Research, 1967, 21, 857-868.	4.5	46
311	Myocardial High Energy Phosphate Stores in Cardiac Hypertrophy and Heart Failure. Circulation Research, 1967, 21, 365-374.	4.5	124
312	Amelioration of Angina Pectoris in Idiopathic Hypertrophic Subaortic Stenosis with Beta-Adrenergic Blockade. Circulation, 1967, 35, 847-851.	1.6	165
313	Physiological Differences between the Effects of Neuronally Released and Bloodborne Norepinephrine on Beta Adrenergic Receptors in the Arterial Bed of the Dog. Circulation Research, 1967, 21, 217-228.	4.5	65
314	Prosthetic Replacement of the Mitral Valve. Circulation, 1967, 35, 962-979.	1.6	112
315	Contractile State of Cardiac Muscle Obtained from Cats with Experimentally Produced Ventricular Hypertrophy and Heart Failure. Circulation Research, 1967, 21, 341-354.	4.5	518
316	CLINICAL AND HEMODYNAMIC APPRAISAL OF BETA ADRENERGIC BLOCKING DRUGS. Annals of the New York Academy of Sciences, 1967, 139, 952-967.	3.8	26
317	Combined Prosthetic Replacement of the Mitral and Aortic Valves. Circulation, 1967, 35, 115-23.	1.6	12
318	Circulatory Effects of Acute Expansion of Blood Volume:. Circulation Research, 1966, 19, 26-32.	4.5	75
319	The Assessment of Operative Results in Congenital Heart Disease by Intraoperative Indicator-Dilution Curves. Circulation, 1966, 33, 263-269.	1.6	11
320	Effects of Changes in Body Position on the Severity of Obstruction to Left Ventricular Outflow in Idiopathic Hypertrophic Subaortic Stenosis. Circulation, 1966, 33, 374-382.	1.6	26
321	Ligation of the Main Pulmonary Artery and Systemic-Pulmonary Arterial Anastomosis. Circulation, 1966, 34, 55-60.	1.6	3
322	Studies on Digitalis. Circulation, 1966, 34, 532-539.	1.6	116
323	The Mechanism of the Intraventricular Pressure Gradient in Idiopathic Hypertrophic Subaortic Stenosis. Circulation, 1966, 34, 558-578.	1.6	177
324	Left Ventricular Performance During Muscular Exercise in Patients with and without Cardiac Dysfunction. Circulation, 1966, 34, 597-608.	1.6	172

#	ARTICLE	IF	CITATIONS
325	Reduction of the Cardiac Response to Postganglionic Sympathetic Nerve Stimulation in Experimental Heart Failure. Circulation Research, 1966, 19, 51-56.	4.5	126
326	Myocardial High Energy Phosphate Stores in Acutely Induced Hypoxic Heart Failure. Circulation Research, 1966, 19, 221-229.	4.5	83
327	Acute Severe Mitral Regurgitation Secondary to Ruptured Chordae Tendineae. Circulation, 1966, 33, 58-70.	1.6	153
328	Alterations in Regional Pulmonary Blood Flow in Mitral Valve Disease Studied by Radioisotope Scanning. Circulation, 1966, 34, 363-376.	1.6	117
329	Determinants of atrial contractile force in the intact heart. American Journal of Physiology, 1965, 209, 1061-1068.	5.0	108
330	Velocity of contraction as a determinant of myocardial oxygen consumption. American Journal of Physiology, 1965, 209, 919-927.	5.0	331
331	Mechanism of increase of myocardial oxygen uptake produced by catecholamines ¹ . American Journal of Physiology, 1965, 209, 913-918.	5.0	86
332	The Incidence and Management of "Medical" Complications Following Cardiac Operations. Circulation, 1965, 32, 608-619.	1.6	52
333	Mechanism of Norepinephrine Depletion in Experimental Heart Failure Produced by Aortic Constriction in the Guinea Pig. Circulation Research, 1965, 17, 312-321.	4.5	147
334	An Intrinsic Adrenergic Vasodilator Mechanism in the Coronary Vascular Bed of the Dog. Circulation Research, 1965, 16, 376-382.	4.5	94
335	The Effects of Nitroglycerin and Amyl Nitrite on Arteriolar and Venous Tone in the Human Forearm. Circulation, 1965, 32, 755-766.	1.6	443
336	A Method for the Detection and Quantification of Impaired Sodium Excretion. Circulation, 1965, 32, 223-231.	1.6	78
337	Effects of Changing Heart Rate in Man by Electrical Stimulation of the Right Atrium. Circulation, 1965, 32, 549-558.	1.6	256
338	Studies on Cardiac Dimensions in Intact Unanesthetized Man. Circulation, 1965, 32, 767-771.	1.6	169
339	Editorial. Circulation, 1965, 32, 677-681.	1.6	25
340	Electroaugmentation of Ventricular Performance and Oxygen Consumption by Repetitive Application of Paired Electrical Stimuli. Circulation Research, 1965, 16, 332-342.	4.5	120
341	Relative Roles of the Sympathetic and Parasympathetic Nervous Systems in the Reflex Control of Heart Rate. Circulation Research, 1965, 16, 363-375.	4.5	250
342	Effects of Aortic Regurgitation on Left Ventricular Performance. Circulation, 1965, 31, .	1.6	12

#	ARTICLE	IF	CITATIONS
343	Circulatory response to hypoxia in unanesthetized dogs with and without cardiac denervation. American Journal of Physiology, 1964, 207, 753-758.	5.0	27
344	Effect of hemorrhagic shock on release of norepinephrine by tyramine. American Journal of Physiology, 1964, 206, 1262-1266.	5.0	6
345	The Circulatory Response of Patients with Idiopathic Hypertrophic Subaortic Stenosis to Nitroglycerin and to the Valsalva Maneuver. Circulation, 1964, 29, 422-431.	1.6	131
346	Diagnostic Value of the First and Second Derivatives of the Arterial Pressure Pulse in Aortic Valve Disease and in Hypertrophic Subaortic Stenosis. Circulation, 1964, 30, 90-100.	1.6	40
347	The Study of Left Ventricular Function in Man by Increasing Resistance to Ventricular Ejection with Angiotensin. Circulation, 1964, 29, 739-749.	1.6	292
348	Studies on Starling's Law of the Heart. Circulation, 1964, 30, 719-727.	1.6	103
349	Effects of Beta Adrenergic Blockade on the Circulation, with Particular Reference to Observations in Patients with Hypertrophic Subaortic Stenosis. Circulation, 1964, 29, 84-98.	1.6	219
350	Studies on Cardiac Dimensions in Intact, Unanesthetized Man. Circulation, 1964, 29, 186-194.	1.6	49
351	Idiopathic Hypertrophic Subaortic Stenosis: II. Operative Treatment and the Results of Pre- and Postoperative Hemodynamic Evaluations. Circulation, 1964, 29, .	1.6	52
352	Idiopathic Hypertrophic Subaortic Stenosis: I. A Description of the Disease Based Upon an Analysis of 64 Patients. Circulation, 1964, 29, SUPPL 4:3-119.	1.6	365
353	Idiopathic myocardial hypertrophy without congestive heart failure or obstruction to blood flow. American Journal of Medicine, 1963, 35, 7-19.	1.5	89
354	Interatrial Communication and Left Atrial Hypertension. Circulation, 1963, 28, 853-860.	1.6	53
355	Studies on the Function of the Adrenergic Nerve Endings in the Heart. Circulation, 1963, 28, 958-969.	1.6	52
356	Study of the Relationship Between the Neurotransmitter Store and Adrenergic Nerve Block Induced by Reserpine and Guanethidine. Circulation Research, 1963, 12, 264-268.	4.5	80
357	The Syndrome of Severe Mitral Regurgitation with Normal Left Atrial Pressure. Circulation, 1963, 27, 29-35.	1.6	181
358	Uptake and Metabolism of Tritiated Norepinephrine in the Isolated Canine Heart. Circulation Research, 1963, 12, 220-227.	4.5	29
359	Relationships Between the Release and Tissue Depletion of Norepinephrine from the Heart by Guanethidine and Reserpine. Circulation Research, 1963, 12, 256-263.	4.5	37
360	Starling's law of the heart. VII: Ventricular function in closed-chest unanesthetized dogs. American Journal of Physiology, 1963, 204, 439-445.	5.0	17

#	ARTICLE	IF	CITATIONS
361	Congenital Aortopulmonary Septal Defect. Circulation, 1962, 25, 463-476.	1.6	57
362	Determination of Fraction of Left Ventricular Volume Ejected per Beat and of Ventricular End-Diastolic and Residual Volumes. Circulation, 1962, 25, 674-685.	1.6	138
363	Transseptal Left Heart Catheterization. Circulation, 1962, 25, 15-21.	1.6	263
364	Hemodynamic-Phonocardiographic Correlations of the Fourth Heart Sound in Aortic Stenosis. Circulation, 1962, 26, 92-98.	1.6	52
365	The Effects of Surgical Abolition of Left-to-Right Shunts on the Pulmonary Vascular Dynamics of Patients with Pulmonary Hypertension. Circulation, 1962, 26, 1270-1278.	1.6	50
366	Analysis of the Acute Circulatory Effects of Guanethidine and Bretylium. Circulation Research, 1962, 10, 83-88.	4.5	27
367	Editorial. Circulation, 1962, 26, 161-165.	1.6	67
368	Augmentation of the Plasma Nor-Epinephrine Response to Exercise in Patients with Congestive Heart Failure. New England Journal of Medicine, 1962, 267, 650-654.	27.0	440
369	Studies on Digitalis. Circulation, 1962, 26, 166-173.	1.6	108
370	Studies on Starling's Law of the Heart. Circulation, 1962, 26, 516-524.	1.6	39
371	Effects of Reserpine and Guanethidine on Venous Reflexes. Circulation Research, 1962, 11, 889-894.	4.5	25
372	Circulatory effects of profound hypothermia during extracorporeal circulation. American Journal of Physiology, 1962, 202, 523-526.	5.0	11
373	STUDIES ON THE FIRST DERIVATIVE OF THE VENTRICULAR PRESSURE PULSE IN MAN. Journal of Clinical Investigation, 1962, 41, 80-91.	8.2	379
374	Studies on Starling's Law of the Heart. Circulation, 1961, 24, 633-642.	1.6	429
375	Precordial Scanning. Circulation, 1961, 23, 21-29.	1.6	21
376	A Hemodynamic Technic for the Detection of Hypertrophic Subaortic Stenosis. Circulation, 1961, 23, 189-194.	1.6	235
377	A Simplified Technic for the Detection of Patent Ductus Arteriosus and of Other Left-to-Right Shunts Originating from the Aorta. Circulation, 1961, 23, 279-285.	1.6	12
378	Studies on Digitalis. Circulation, 1961, 23, 376-382.	1.6	64

#	ARTICLE	IF	CITATIONS
379	Use of Krypton ⁸⁵ for the Measurement of Cardiac Output by the Single-Injection Indicator-Dilution Technique. Circulation Research, 1961, 9, 984-988.	4.5	4
380	Influence of Carotid Baroreceptors and Vasoactive Drugs on Systemic Vascular Volume and Venous Distensibility. Circulation Research, 1961, 9, 75-82.	4.5	56
381	Left Atrial and Left Ventricular Pressures in Subjects without Cardiovascular Disease. Circulation, 1961, 24, 267-269.	1.6	163
382	Studies on Starling's Law of the Heart. Circulation Research, 1960, 8, 1254-1263.	4.5	88
383	Left Heart Catheterization by the Transseptal Route. Circulation, 1960, 22, 927-934.	1.6	119
384	Intracardiac Injection of Radioactive Krypton. Circulation, 1960, 21, 1126-1133.	1.6	32
385	A new technic for left ventricular angiocardiography and transseptal left heart catheterization. American Journal of Cardiology, 1960, 6, 1062-1064.	1.6	217
386	Functional Aortic Stenosis. Circulation, 1959, 20, 181-189.	1.6	181
387	Detection of Pulmonic and Tricuspid Valvular Regurgitation by Means of Indicator Solutions. Circulation, 1959, 20, 561-568.	1.6	36
388	Supravalvular Aortic Stenosis. Circulation, 1959, 20, 1003-1010.	1.6	113
389	A Simplified Indicator-Dilution Technic for the Localization of Left-to-Right Circulatory Shunts. Circulation, 1959, 20, 875-880.	1.6	26
390	Transseptal left atrial puncture. American Journal of Cardiology, 1959, 3, 653-655.	1.6	244
391	Origin of Heart Sounds as Elucidated by Analysis of the Sequence of Cardiodynamic Events. Circulation, 1958, 18, 971-974.	1.6	30
392	Congenital Aortic Stenosis. Circulation, 1958, 18, 1091-1104.	1.6	46
393	A Method for the Detection and Estimation of Aortic Regurgitant Flow in Man. Circulation, 1958, 17, 505-511.	1.6	57
394	Pulsus Alternans in Aortic Stenosis. Circulation, 1958, 18, 64-70.	1.6	33
395	The Nitrous Oxide Test. Circulation, 1958, 17, 284-291.	1.6	51
396	Left Atrial Pressure Pulse in Mitral Valve Disease. Circulation, 1957, 16, 399-405.	1.6	87

#	ARTICLE	IF	CITATIONS
397	Left Heart Catheterization by the Transbronchial Route. <i>Circulation</i> , 1957, 16, 1033-1039.	1.6	71
398	The Haemodynamic Effects of Circulatory Drugs in Patients with Idiopathic Hypertrophic Subaortic Stenosis. <i>Novartis Foundation Symposium</i> , 0, , 172-188.	1.1	1
399	Operative Treatment in Idiopathic Hypertrophic Subaortic Stenosis: Surgical Methods and the Results of Operation. <i>Novartis Foundation Symposium</i> , 0, , 250-265.	1.1	0
400	Cardiac xenotransplantation: a new path for the treatment of advanced heart failure?. <i>European Heart Journal</i> , 0, , .	2.2	1
401	Control of residual dyslipidaemic risk. <i>European Heart Journal</i> , 0, , .	2.2	4